Could acoziborole eliminate sleeping sickness in Africa?
European Pharmaceutical Review
DECEMBER 1, 2022
Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. The study demonstrated acoziborole has a favourable safety profile, with no significant drug-related safety signals reported.
Let's personalize your content